EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY 4.0

Subendocardial quantification enhances coronary artery disease detection in 18F-flurpiridaz PET

Valerie Builoff, Mark Lemley, Robert J H Miller, Hidesato Fujito, Giselle Ramirez, Paul Kavanagh, Christopher Buckley, Marcelo Di Carli, Daniel S Berman, Piotr Slomka iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025-07 · 52 (9) · 3342-3352

DOI: 10.1007/s00259-025-07174-6 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 05.03.2025. Verfasst von Valerie Builoff und 9 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine, (Division of Artificial Intelligence in Medicine), and Imaging, Cedars-Sinai Medical Center, 6500 Wilshire Boulevard, Los An…. Hauptthemen laut MEDLINE: Coronary Artery Disease, Positron-Emission Tomography, Pyridazines, Aminopyridines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIBIB NIH HHS, NHLBI NIH HHS, Cedars-Sinai Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The new high resolution positron emission tomography (PET) myocardial perfusion imaging tracer, 18 F-flurpiridaz, is set to enter clinical use soon following its recent regulatory approval. We developed an approach for evaluating subendocardial analysis for stress total perfusion deficit (TPD) and ischemic TPD, assessed its performance for detection of coronary artery disease (CAD) and compared these measures to transmural analysis and expert physician assessments.

Methods

Myocardial perfusion image data from the 18 F-flurpiridaz phase III clinical trial (NCT01347710) were used. The subendocardial layer was automatically defined on the left ventricular contours and used for the derivation of polar maps. Areas under the receiver operating characteristic curve (AUC) for quantitative and visual measures were evaluated for detecting CAD, defined as ≥ 50% stenosis by invasive coronary angiography.

Results

In total, 753 cases were analyzed, with a median age of 63 (interquartile range 56,69) and 69% male. AUC for detecting ≥ 50% stenosis was higher for subendocardial than transmural analysis for stress (0.795 vs. 0.762, respectively; p = 0.013) and ischemic (0.795 vs. 0.767, respectively; p = 0.049) TPD. Subendocardial and transmural TPD achieved diagnostic performance greater than or comparable to that of the readers’ assessments in the total population as well as across subgroups of interest.

Conclusion

Subendocardial analysis of ischemic perfusion improves the detection of CAD compared to transmural quantitative analysis or expert visual reading. These measures can be derived automatically with minimal user interaction. Integrating TPD quantitative measures could standardize the diagnostic approach for this novel tracer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseasePositron-Emission TomographyPyridazinesAminopyridinesEndocardiumHumansMaleMiddle AgedFemaleAgedMyocardial Perfusion Imaging

Stichwörter der Autor:innen

18F-flurpiridazCoronary artery diseasePET-MPIPerfusion quantitationSubendocardial perfusion

Substanzen

PyridazinesBMS 747158-02Aminopyridines

Autor:innen und Institutionen

  • Departments of Medicine, (Division of Artificial Intelligence in Medicine), and Imaging, Cedars-Sinai Medical Center, 6500 Wilshire Boulevard, Los Angeles, CA, 90048, USA.
  • Department of Cardiac Sciences, University of Calgary, Calgary, AB, Canada.
  • Department of Cardiology, Nihon University Itabashi Hospital, Tokyo, Japan.
  • Pharmaceutical Diagnostics, GE Healthcare, Buckinghamshire, UK.
  • Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Departments of Medicine, (Division of Artificial Intelligence in Medicine), and Imaging, Cedars-Sinai Medical Center, 6500 Wilshire Boulevard, Los Angeles, CA, 90048, USA. Piotr.Slomka@cshs.org.

ORCID-Profile: Piotr Slomka

Förderung

  • NIBIB NIH HHS
  • NHLBI NIH HHS
  • Cedars-Sinai Medical Center

Zitieren

APA

Builoff, V., Lemley, M., Miller, R. J. H., Fujito, H., Ramirez, G., Kavanagh, P., Buckley, C., Di Carli, M., Berman, D. S., & Slomka, P. (2025). Subendocardial quantification enhances coronary artery disease detection in 18F-flurpiridaz PET. European Journal of Nuclear Medicine and Molecular Imaging, 52(9), 3342-3352. https://doi.org/10.1007/s00259-025-07174-6

Vancouver

Builoff V, Lemley M, Miller RJH, Fujito H, Ramirez G, Kavanagh P, et al. Subendocardial quantification enhances coronary artery disease detection in 18F-flurpiridaz PET. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(9):3342-3352. doi:10.1007/s00259-025-07174-6

BibTeX
@article{Builoff2025,
  author = {Builoff, Valerie and Lemley, Mark and Miller, Robert J H and Fujito, Hidesato and Ramirez, Giselle and Kavanagh, Paul and Buckley, Christopher and Di Carli, Marcelo and Berman, Daniel S and Slomka, Piotr},
  title = {Subendocardial quantification enhances coronary artery disease detection in 18F-flurpiridaz PET},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {9},
  pages = {3342--3352},
  doi = {10.1007/s00259-025-07174-6}
}
Kostenlos starten →